Loading
A phase 1/2 trial of Nemtabrutinib in mantle cell lymphoma and diffuse large b-cell lymphoma, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), active and no longer recruiting.
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) is a phase 1/2 interventional study registered as NCT03162536 by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), with 190 participants planned, started 2017-06-26 and due to reach its primary completion in 2027-09-17. Interventions recorded: Nemtabrutinib. Conditions listed: Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nemtabrutinib, Mantle cell lymphoma, Follicular lymphoma, Merck & Co. (MSD).
Shares Nemtabrutinib, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/